The past few months have witnessed the most intense and prolonged criticism of England’s National Health Service (NHS) in its 65-year history. Some critics have suggested that the NHS faces a crisis that can be resolved only by altering the fundamental principle on which it was founded — provision of funding from general taxation, with care being free at the point of use. Although the criticism was sparked by a February report on an inquiry into shortcomings at one hospital, the problems originated in 2010, when two profound forces were unleashed on the NHS: public-sector financial austerity and administrative reorganization. Together, these three factors have created the current turmoil.

Never before has the NHS had to cope with no increase in funding for a sustained period. With rising demand, the NHS is required to improve its productivity at an unprecedented rate of 4% per year. The government is convinced that to achieve this improvement, two fundamental changes are needed.

The first concerns the local commissioning organizations that are responsible for purchasing hospital and community services for their geographically defined populations of 200,000 to 1 million people. The 151 existing administrative bodies called Primary Care Trusts, which were led by nonclinical managers, have been replaced by 212 Clinical Commissioning Groups that are led by primary care doctors (general practitioners [GPs]) who, the government believes, will be more effective in controlling the use of the £60 billion (approximately $90 billion) spent on secondary and community care services. (Spending on tertiary care — £20 billion [$30 billion] — will be managed at a national level by a new entity called NHS England.) The second means of achieving better productivity is by increasing the competition among providers of hospital and community services through the greater use of non-NHS providers (including private for-profit, not-for-profit, and charity or volunteer organizations).

Prolonged financial stringency and a reorganization were challenging enough without a high-profile report suggesting that NHS hospitals may not be safe. The Francis Report on the inquiry into the Mid Staffordshire NHS Foundation Trust told a sad and troubling story of a hospital in which the humanity of care in some wards was appalling and in which the proportion of deaths deemed avoidable may have been higher than the 5% observed elsewhere in England and in other high-income countries. Despite uncertainty about the appropriateness of allowing public inquiries to influence policy, the government has responded by announcing sever-
The third challenge is a lack of managerial capacity, stemming largely from the government’s imposition of a reorganization that had little support from key staff members. This problem has been exacerbated by widespread criticism of managers, in the wake of the Francis Report, by members of the public, the media, and politicians. Although criticisms of some clinical and managerial staff were justified, wholesale condemnation was inappropriate and has contributed to the departure of some excellent managers (particularly when generous retirement options were available). The loss of managers is particularly apparent in the commissioning arena, where the effects will be intensified by the shifting of responsibility to GPs, most of whom will initially lack appropriate experience and training. Although they will receive technical help, it is unclear whether the initial enthusiasm of those GPs who have opted to take on this role will last. The honeymoon might end when GPs realize how uncomfortable it can be to ration care to patients and reduce funds for their local hospital.

Finally, there is concern that the way the NHS has been reorganized will impede attempts to achieve greater integration of services across health care and with social services — integration that is essential to achieving efficient, high-quality care.

So, will the NHS survive these challenges? There are three reasons for optimism. First, there are already examples of enterprising clinicians, managers, and politicians working together to reengineer their local services in imaginative ways. Second, despite legitimate concerns about the quality of some services, public support for the NHS is undiminished, as witnessed by the inclusion of a celebration of the NHS in the Olympics opening ceremony last July and as reflected in national surveys. Public enthusiasm is mirrored not only by that of most clinicians and managers but also by the majority of politicians (including the current gov-
NICE: Moving Onward
Michael D. Rawlins, M.D.

The National Institute for Clinical Excellence (NICE) was established in 1999, primarily to offer professionals in Britain’s National Health Service (NHS) advice on providing care that meets the highest attainable standards. NICE’s role was expanded in 2005 to include provision of analogous advice to the broader public health community on preventing ill health and maintaining good health. (The name was changed to the National Institute for Health and Clinical Excellence, but the acronym NICE has continued to be used.)

To meet these objectives, NICE now has three different strands of responsibilities (see table),¹ and its budget from the government has increased tenfold. Much attention, however, continues to focus on NICE’s technology appraisals and clinical-guideline programs.

Since 2000, the Institute has been publishing technology appraisals — assessments of the clinical effectiveness and cost-effectiveness of (mainly) new pharmaceutical products, including whether providing them constitutes a good use of NHS resources. Contrary to popular mythology, NICE rejects less than 15% of technologies on the grounds of cost-ineffectiveness. In recent years, manufacturers have increasingly been offering the NHS, through NICE, “patient access schemes,” which can substantially reduce the price of products and render them more likely to be considered cost-effective. Such offers have sometimes led a product with a negative provisional assessment to gain a positive final one, and occasionally decisions have been reversed because manufacturers have submitted additional evidence about a product’s clinical effectiveness.

NICE’s clinical guidelines improve the quality of care provided to NHS patients. For example, after the publication of a guide